Debiopharm International SA: DEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER

Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer

Related Keywords

Spain ,London ,City Of ,United Kingdom ,Switzerland ,Prnewswire Debiopharm ,Luis Paz ,Esteban Rodrigo Imedio ,Oncology Research Development ,Twitter ,Head Of Communications ,Hebron Hospital ,Luis Paz Ares Rodr ,Senior Medical Director ,Oncology Research ,Small Cell Lung Cancer ,Damage Repair ,Rev Dis Primers ,Gefallene Big Techs ,Debiopharm ,Nternational ,Aunches ,Hase ,Research ,Mall ,Fell ,Young ,Dancer ,Ith ,Wee1 ,Inhibitor ,Debio ,123 ,Outsmart ,